Table 1 Clinical, virological, and immunological patient characteristics.

From: HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules

Infection status

Age/Sex

HLA-class II

Genotype

Peak VL (IU/ml)

VL (IU/ml)*

Peak ALT (U/l)

ALT

(U/l)*

Longitudinal samples

Outcome

Therapy

aHCV 1

68/f

DRB1*01:01, *14:01

1a

/

4000000

/

51

yes

cHCV/SVR

peg-IFN/RBV (24 W)

aHCV 2

42/m

DRB1*14:01, *15:01

1a

70000

70000

558

558

no

cHCV

/

aHCV 3

51/f

DRB1*03:01, *15:01

2b

8000

8000

1548

798

no

Sp. R

/

aHCV 4

54/f

DRB1*01:02,*03:01

3a

4000000

30000000

1273

1084

yes

Sp. R

/

aHCV 5

47/f

DRB1*01:02, *15:01

n.a.

Llod

Llod

63

63

yes

Sp. R

/

aHCV 6

22/f

DRB1*01:01, *03:01

1a

400000

30000

368

40

yes

cHCV/SVR

peg-IFN/RBV (24 W)

aHCV 7

32/m

DRB1*13:02,*15:01

n.a.

70000

70000

1317

91

no

Sp. R

/

aHCV 8

44/m

DRB1*01:01, *03:01

1a

30000000

90000

4316

1762

yes

cHCV/SVR

peg-IFN/RBV (24 W)

aHCV 9

38/f

DRB1*03:01, 15:06

3

2070000

30500

521

115

no

cHCV

 

aHCV 10

39/m

DRB1*04:01, *15:01

1a

18040000

140

2387

51

yes

cHCV/SVR

peg-IFN/RBV (24 W)

rHCV 11

38/m

DRB1*11:01, *13:02

n.a.

Llod

Llod

32

22

no

/

/

rHCV 12

36/m

DRB1*01:01, *11:01

n.a.

Llod

Llod

23

23

no

/

/

rHCV 13

36/m

DRB1*07:01,*15:01

n.a.

Llod

Llod

66

43

no

/

/

rHCV 14

48/f

DRB1*01:01,*-

n.a.

Llod

Llod

15

10

no

/

/

rHCV15

51/f

DRB1*01:01,*14:01

n.a.

Llod

Llod

94

48

no

/

/

rHCV 16

26/m

DRB1*11:02, *12:01

n.a.

Llod

Llod

90

86

no

/

/

rHCV 17

44/m

DRB1*01:01, *27:05

n.a.

Llod

Llod

84

20

no

/

/

rHCV 18

68/m

DRB1*08:03, *11:01

n.a.

Llod

Llod

32

30

no

/

/

cHCV 19

65/m

DRB1*11:01,*15:01

1a

1000000

800000

100

100

no

/

/

cHCV 20

60/f

DRB1*04:01, *15:01

1b

9000000

9000000

68

54

no

/

/

cHCV 21

28/f

DRB1*13:01, *15:01

1b

2000000

2000000

43

43

yes

SVR

Ledipasvir/Sofusbuvir (12 W)

cHCV 22

56/m

DRB1*11:02, *15:01

1a

30000

10000

374

75

no

/

/

cHCV 23

63/f

DRB1*07:01, *15:01

1b

10000000

2000000

138

54

yes

SVR

Ledipasvir/Sofosbuvir (12 W)

cHCV 24

43/m

DRB1*04:04,*15:01

1b

6000000

5230000

208

128

yes

SVR

Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir (12 W)

cHCV 25

43/f

DRB1*13:01, *15:03

1a

8741517

2884373

43

43

no

/

/

cHCV 26

55/m

DRB1*15:01, *13:01

3a

2775

2775

91

65

no

/

/

cHCV 27

40/f

DRB1*03:01,*15:01

3

4330000

4330000

42

30

no

/

/

cHCV 28

39/f

DRB1*04:08, *15:02

3

24300000

24300000

71

50

no

/

/

cHCV 29

46/m

DRB1*07:01, *15:01

3

15900000

13300000

208

127

yes

SVR

Sofusbuvir/Velpatasvir (12 W)

tHCV 30

62/m

DRB1*01:01

n.a.

Llod

Llod

58

58

no

SVR

peg-IFN/RBV (24 W)

tHCV 31

37/m

DRB1*01:01, *07:01

3

25100000

26

319

43

no

SVR

Sofusbuvir/Velpatasvir (12 W)

tHCV 32

37/m

DRB1*15:01, -

3

17800000

Llod

25

25

no

SVR

Sofusbuvir/Velpatasvir (12 W)

tHCV 33

52/m

DRB1*01:01, *11:01

1a

2000000

Llod

272

107

no

SVR

peg-IFN/RBV (48 W)

tHCV 34

39/m

DRB1*07:01, *11:01

3

850000

Llod

157

25

no

SVR

Sofusbuvir/Velpatasvir (12 W)